BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

5366

543329

WINDLAS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

WINDLAS BIOTECH LIMITED performance

Today’s low

Today’s high

₹ 958.10 ₹ 990.50
₹ 965.50

52 week low

52 week high

₹ 495.65 ₹ 1198.25
₹ 965.50

Open Price

₹ 980.00

Prev. Close

₹ 974.90

Volume (Shares)

37100.00

Total traded value

₹ 358.20

Upper Circuit

₹ 1169.80

Lower Circuit

₹ 780.00

info

WINDLAS BIOTECH LIMITED Share Price Update

As of the latest trading session, WINDLAS BIOTECH LIMITED share price is currently at ₹ 965.5, which is down by ₹ -9.40 from its previous closing. Today, the stock has fluctuated between ₹ 958.10 and ₹ 990.50. Over the past year, WINDLAS BIOTECH LIMITED has achieved a return of 77.62 %. In the last month alone, the return has been -4.03 %. Read More...

WINDLAS BIOTECH LIMITED fundamentals


  • Market cap (Cr)

    2,008.10

  • P/E Ratio (TTM)

    33.21

  • Beta

    1.29

  • Book Value / share

    225.62

  • Return on equity

    13.63%

  • EPS (TTM)

    29.34

  • Dividend yield

    0.56%

  • Net profit/quarter (Cr)

    15.23

info icon alternate text
  • Market cap (Cr)

    1,997.91

  • P/E Ratio (TTM)

    33.21

  • Beta

    1.23

  • Book Value / share

    225.62

  • Return on equity

    13.63%

  • EPS (TTM)

    29.34

  • Dividend yield

    0.56%

  • Net profit/quarter (Cr)

    15.23

info icon alternate text

WINDLAS BIOTECH LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 195.02
Operating Expense 178.78
Net Profit 15.23
Net Profit Margin (%) 7.80
Earnings Per Share (EPS) 7.29
EBITDA 28.37
Effective Tax Rate (%) 23.73
Particulars SEP 2024 (Values in Cr)
Revenue 187.00
Operating Expense 171.54
Net Profit 15.66
Net Profit Margin (%) 8.37
Earnings Per Share (EPS) 7.49
EBITDA 27.89
Effective Tax Rate (%) 22.81
Particulars JUN 2024 (Values in Cr)
Revenue 175.15
Operating Expense 160.97
Net Profit 13.48
Net Profit Margin (%) 7.69
Earnings Per Share (EPS) 6.47
EBITDA 25.00
Effective Tax Rate (%) 26.37
Particulars MAR 2024 (Values in Cr)
Revenue 171.29
Operating Expense 153.17
Net Profit 16.95
Net Profit Margin (%) 9.89
Earnings Per Share (EPS) 8.15
EBITDA 26.38
Effective Tax Rate (%) 24.86
Particulars DEC 2023 (Values in Cr)
Revenue 162.21
Operating Expense 145.58
Net Profit 15.10
Net Profit Margin (%) 9.30
Earnings Per Share (EPS) 7.26
EBITDA 23.50
Effective Tax Rate (%) 23.77
Particulars MAR 2024 (Values in Cr)
Revenue 630.96
Operating Expense 567.40
Net Profit 58.14
Net Profit Margin (%) 9.21
Earnings Per Share (EPS) 27.95
EBITDA 91.55
Effective Tax Rate (%) 24.51
Particulars MAR 2023 (Values in Cr)
Revenue 513.08
Operating Expense 466.00
Net Profit 42.64
Net Profit Margin (%) 8.31
Earnings Per Share (EPS) 19.71
EBITDA 70.21
Effective Tax Rate (%) 25.25
Particulars MAR 2022 (Values in Cr)
Revenue 465.93
Operating Expense 426.60
Net Profit 38.56
Net Profit Margin (%) 8.27
Earnings Per Share (EPS) 18.81
EBITDA 59.61
Effective Tax Rate (%) 16.24
Particulars MAR 2021 (Values in Cr)
Revenue 427.60
Operating Expense 387.17
Net Profit 5.01
Net Profit Margin (%) 1.17
Earnings Per Share (EPS) 2.75
EBITDA 25.43
Effective Tax Rate (%) 55.18
Particulars MAR 2024 (Values in Cr)
Book Value / Share 216.34
ROE % 13.66
ROCE % 18.07
Total Debt to Total Equity 0.01
EBITDA Margin 14.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 192.24
ROE % 10.70
ROCE % 14.23
Total Debt to Total Equity 0.01
EBITDA Margin 13.68
Particulars MAR 2022 (Values in Cr)
Book Value / Share 181.14
ROE % 12.83
ROCE % 14.77
Total Debt to Total Equity 0.07
EBITDA Margin 12.69
Particulars MAR 2021 (Values in Cr)
Book Value / Share 310.59
ROE % 15.19
ROCE % 18.88
Total Debt to Total Equity 0.15
EBITDA Margin 13.47
Particulars MAR 2020 (Values in Cr)
Book Value / Share 327.03
ROE % 8.04
ROCE % 11.66
Total Debt to Total Equity 0.15
EBITDA Margin 11.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 216.51
ROE % 13.63
ROCE % 18.03
Total Debt to Total Equity 0.01
EBITDA Margin 14.51
Particulars MAR 2023 (Values in Cr)
Book Value / Share 192.42
ROE % 10.69
ROCE % 14.22
Total Debt to Total Equity 0.01
EBITDA Margin 13.68
Particulars MAR 2022 (Values in Cr)
Book Value / Share 181.30
ROE % 12.98
ROCE % 14.91
Total Debt to Total Equity 0.07
EBITDA Margin 12.79
Particulars MAR 2021 (Values in Cr)
Book Value / Share 310.39
ROE % 9.39
ROCE % 18.75
Total Debt to Total Equity 0.14
EBITDA Margin 13.51
Particulars MAR 2020 (Values in Cr)
Book Value / Share 337.66
ROE % 10.94
ROCE % 14.02
Total Debt to Total Equity 0.14
EBITDA Margin 12.66
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 30.94
Total Assets 626.20
Total Liabilities 626.20
Total Equity 449.93
Share Outstanding 20798575
Price to Book Ratio 2.37
Return on Assets (%) 9.29
Return on Capital (%) 12.93
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 25.45
Total Assets 528.97
Total Liabilities 528.97
Total Equity 402.27
Share Outstanding 20926628
Price to Book Ratio 1.17
Return on Assets (%) 8.05
Return on Capital (%) 10.58
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 113.82
Total Assets 491.01
Total Liabilities 491.01
Total Equity 394.77
Share Outstanding 21794375
Price to Book Ratio 1.16
Return on Assets (%) 7.75
Return on Capital (%) 9.5
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 31.11
Total Assets 296.12
Total Liabilities 296.12
Total Equity 199.11
Share Outstanding 6411063
Price to Book Ratio 0.00
Return on Assets (%) 5.34
Return on Capital (%) 6.87
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 18.38
Total Assets 338.48
Total Liabilities 338.48
Total Equity 209.65
Share Outstanding 6411063
Price to Book Ratio 0.00
Return on Assets (%) 4.78
Return on Capital (%) 6.99
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 30.89
Total Assets 626.15
Total Liabilities 626.15
Total Equity 450.29
Share Outstanding 20798575
Price to Book Ratio 2.37
Return on Assets (%) 9.28
Return on Capital (%) 12.91
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 25.45
Total Assets 529.00
Total Liabilities 529.00
Total Equity 402.66
Share Outstanding 20926628
Price to Book Ratio 1.17
Return on Assets (%) 8.06
Return on Capital (%) 10.58
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 113.80
Total Assets 491.02
Total Liabilities 491.02
Total Equity 395.12
Share Outstanding 21794375
Price to Book Ratio 1.16
Return on Assets (%) 7.85
Return on Capital (%) 9.61
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 30.95
Total Assets 295.99
Total Liabilities 295.99
Total Equity 198.99
Share Outstanding 6411063
Price to Book Ratio 0.00
Return on Assets (%) 1.69
Return on Capital (%) 2.18
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 18.38
Total Assets 343.80
Total Liabilities 343.80
Total Equity 216.47
Share Outstanding 6411063
Price to Book Ratio 0.00
Return on Assets (%) 6.53
Return on Capital (%) 9.41
Particulars MAR 2024 (Values in Cr)
Net Income 77.09
Cash from Operations 127.60
Cash from Investing -92.06
Cash from Financing -15.29
Net change in Cash 1.60
Free Cash Flow 165.29
Particulars MAR 2023 (Values in Cr)
Net Income 57.03
Cash from Operations 70.68
Cash from Investing -14.11
Cash from Financing -43.73
Net change in Cash 3.11
Free Cash Flow 141.57
Particulars MAR 2022 (Values in Cr)
Net Income 45.56
Cash from Operations 18.01
Cash from Investing -154.57
Cash from Financing 130.08
Net change in Cash -15.36
Free Cash Flow 32.81
Particulars MAR 2021 (Values in Cr)
Net Income 21.74
Cash from Operations 17.98
Cash from Investing -20.19
Cash from Financing 0.77
Net change in Cash -7.96
Free Cash Flow 23.83
Particulars MAR 2020 (Values in Cr)
Net Income 24.66
Cash from Operations 38.43
Cash from Investing -14.34
Cash from Financing -5.44
Net change in Cash 5.22
Free Cash Flow 53.74
Particulars MAR 2024 (Values in Cr)
Net Income 77.02
Cash from Operations 127.53
Cash from Investing -92.06
Cash from Financing -15.28
Net change in Cash 1.55
Free Cash Flow 165.21
Particulars MAR 2023 (Values in Cr)
Net Income 57.05
Cash from Operations 70.69
Cash from Investing -14.11
Cash from Financing -43.73
Net change in Cash 3.13
Free Cash Flow 141.58
Particulars MAR 2022 (Values in Cr)
Net Income 46.03
Cash from Operations 17.87
Cash from Investing -154.30
Cash from Financing 130.08
Net change in Cash -15.22
Free Cash Flow 32.67
Particulars MAR 2021 (Values in Cr)
Net Income 11.18
Cash from Operations 17.98
Cash from Investing -20.19
Cash from Financing 0.77
Net change in Cash -7.96
Free Cash Flow 23.82
Particulars MAR 2020 (Values in Cr)
Net Income 30.57
Cash from Operations 34.33
Cash from Investing -9.15
Cash from Financing -6.48
Net change in Cash 5.22
Free Cash Flow 44.50
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

WINDLAS BIOTECH LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
965.50 -0.96 redarrow
red-green-graph indicator
12 Bearish
4 Bullish
  • 5 Days 998.90
  • 26 Days 989.20
  • 10 Days 1007.00
  • 50 Days 968.80
  • 12 Days 1006.60
  • 100 Days 952.90
  • 20 Days 997.60
  • 200 Days 892.40
990.33 PIVOT

First Support

951.67

First Resistance

1013.57

Second Support

928.43

Second Resistance

1052.23

Third Support

889.77

Third Resistance

1075.47

RSI

48.01

ADX

17.12

MACD

17.37

Williams % R

-50.53

Commodity Channel Index (CCI)

-36.96

Date

2025-04-29

Week

25377.00

Same Day

24326.00

Month

37154.00

1 Year

1.30

3 Year

0.97

Over 1 Month

-4.03%

down

Over 1 Year

77.62%

down

Over 3 Months

1.64%

down

Over 3 Years

57.33%

down

Over 6 Months

-1.26%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

WINDLAS BIOTECH LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
25.25%
Promoter Holdings
62.33%
FII
1.51%
DII
10.89%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Akw Wbl Family Private Trust (through Its Trustees Ashok Vimla Trusteeship Services Private Limited) 8381340.0 (39.99%) Shareholding of Promoter and Promoter Group
Ashok Kumar Windlass 4400000.0 (20.99%) Shareholding of Promoter and Promoter Group
Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) Fund 1251178.0 (5.97%) Public Shareholding
Vimla Windlass 284000.0 (1.36%) Shareholding of Promoter and Promoter Group
Perpetuity Health To Wealth (h2w) Rising Fund 270000.0 (1.29%) Public Shareholding
Persistence Capital Fund I 229244.0 (1.09%) Public Shareholding
Ajay Kumar Aggarwal 214995.0 (1.03%) Public Shareholding
Pgim India Equity Growth Opportunities Fund-series I 214739.0 (1.02%) Public Shareholding
Prachi Jain Windlass 3.0 (0.0%) Shareholding of Promoter and Promoter Group
Payal Windlass 3.0 (0.0%) Shareholding of Promoter and Promoter Group
Manoj Kumar Windlass 3.0 (0.0%) Shareholding of Promoter and Promoter Group
Hitesh Windlass 3.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

WINDLAS BIOTECH LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
17 Sep 2024 5.5 Final 17 Sep 2024 Equity shares
05 Sep 2023 4.0 Final 05 Sep 2023 Equity shares
09 Sep 2022 3.5 Final 12 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
05 Sep 2023 4.0 Final 05 Sep 2023 Equity shares
09 Sep 2022 3.5 Final 12 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

WINDLAS BIOTECH LIMITED Share Price

Windlas Biotech Limited (formerly known as Windlas Biotech Private Limited) was incorporated in 2001. The Company converted
from a Private Limited Company to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'. A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun.

The Company is engaged in manufacturing and trading of pharmaceutical products. TheIR manufacturing facilities are located at Dehradun in Uttarakhand. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semi-urban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports.

The Company commenced operations at Dehradun Plant -IV in 2010. It provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries.

The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and low-solubility products.

Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible.

In 2020, the Company acquired the erstwhile associate -Windlas Healthcare.

To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.

In August 2021, the Company made an Initial Public Offer of 8,729,023 Equity Shares by raising capital from public aggregating to Rs 401.53 Crore, comprising a Fresh Issue of 3,586,956 Equity Shares aggregating to Rs 165 Crore and an Offer for Sale of 5,142,067 Equity Shares
aggregating to Rs 236.53 Crore.

Parent organization Indian Private
NSE symbol WINDLAS
Founded 2001
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Windlas Biotech Ltd?

Answer Field

The share price of Windlas Biotech Ltd for NSE is ₹ 965.5 and for BSE is ₹ 960.6.

What is the Market Cap of Windlas Biotech Ltd?

Answer Field

The market cap of Windlas Biotech Ltd for NSE is ₹ 20,08.10 Cr. and for BSE is ₹ 19,97.91 Cr. as of now.

What is the 52 Week High and Low of Windlas Biotech Ltd?

Answer Field

The 52 Week High and Low of Windlas Biotech Ltd for NSE is ₹ 1198.25 and ₹ 495.65 and for BSE is ₹ 1197.00 and ₹ 494.70.

How to Buy Windlas Biotech Ltd share?

Answer Field

You can trade in Windlas Biotech Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Windlas Biotech Ltd?

Answer Field

The 1 year returns on the stock has been 77.62%.

What is the Current Share Price of Windlas Biotech Ltd?

Answer Field

Windlas Biotech Ltd share price is for NSE ₹ 965.5 & for BSE ₹ 960.6 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Windlas Biotech Ltd Share?

Answer Field

The market cap of Windlas Biotech Ltd for NSE ₹ 20,08.10 & for BSE ₹ 19,97.91 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Windlas Biotech Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Windlas Biotech Ltd share is 33.21.

What is the PB ratio of Windlas Biotech Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Windlas Biotech Ltd share is 225.62.

How to Buy Windlas Biotech Ltd Share?

Answer Field

You can trade in Windlas Biotech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Windlas Biotech Ltd Share on Bajaj Broking App?

Answer Field

To buy Windlas Biotech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Windlas Biotech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|